The second group consists of ANXA3, ANXA9 and ANXA13. Downregulated expression of ANXA3 and ANXA9 were associated with worse clinical outcomes and upregulated expression of ANXA13 was associated with better clinical outcomes in RCC, suggesting a protective role of ANXA3, ANXA9 and ANXA13 in RCC. Here, ANXA13 is linked to renal cell carcinoma.